NYSE:ADCTBiotechs
Assessing ADC Therapeutics (ADCT) Valuation After Pivotal LOTIS-5 Phase 3 ZYNLONTA Trial Results
ADC Therapeutics (ADCT) has drawn fresh attention after reporting statistically significant Phase 3 LOTIS-5 topline data for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B cell lymphoma, including improved progression free survival versus standard therapy.
See our latest analysis for ADC Therapeutics.
Despite the encouraging LOTIS-5 data, the stock’s 1-day share price return fell 21.97%, extending a 7-day share price decline of 69.71% and a 1-year total shareholder return...